CLARIVATE PLC (CLVT) Form 8-K — Jul 29, 2026
Clarivate reported Q2 2026 revenue of $587.3 million, down 5.5% year-over-year, and reaffirmed its full-year 2026 financial outlook despite recording a net loss of $268.6 million driven by a non-cash goodwill impairment charge of $221.7 million. Adjusted EBITDA remained flat at $247.2 million with a margin of 42.1%, while adjusted net income was $123.1 million or $0.19 per share. The company entered a definitive agreement to sell its Life Sciences & Healthcare segment to Altaris LLC, a transaction valued at approximately 10x 2026E Adjusted EBITDA less capex.
Key figures
- Revenue
- 587300000
- Guidance
- Full Year 2026: ACV Organic Growth 2.0%-3.0%; Revenues $2.30B-$2.42B; Adjusted EBITDA $980M-$1.04B; Adjusted EPS $0.70-$0.80; Free Cash Flow $365M-$435M
- Revenue Yoy
- -5.5%
- Adjusted EPS
- 0.19
- Adjusted EBITDA
- 247200000
- Free Cash Flow H1
- 122900000
- Goodwill Impairment
- 221700000
- Organic Revenue Growth
- -1.5%
Price after filing
Close on the filing date to close N calendar days later (from $2.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.